<code id='21CF770EFF'></code><style id='21CF770EFF'></style>
    • <acronym id='21CF770EFF'></acronym>
      <center id='21CF770EFF'><center id='21CF770EFF'><tfoot id='21CF770EFF'></tfoot></center><abbr id='21CF770EFF'><dir id='21CF770EFF'><tfoot id='21CF770EFF'></tfoot><noframes id='21CF770EFF'>

    • <optgroup id='21CF770EFF'><strike id='21CF770EFF'><sup id='21CF770EFF'></sup></strike><code id='21CF770EFF'></code></optgroup>
        1. <b id='21CF770EFF'><label id='21CF770EFF'><select id='21CF770EFF'><dt id='21CF770EFF'><span id='21CF770EFF'></span></dt></select></label></b><u id='21CF770EFF'></u>
          <i id='21CF770EFF'><strike id='21CF770EFF'><tt id='21CF770EFF'><pre id='21CF770EFF'></pre></tt></strike></i>

          
          WSS
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion